UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On February 20, 2024, RAPT Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from the FDA. The clinical hold determination was based on a serious adverse event of liver failure in one patient in the atopic dermatitis trial, the cause of which is currently unknown but which has been characterized as potentially related to zelnecirnon. Dosing of zelnecirnon has been halted in both clinical trials, as has enrollment of new trial participants. The clinical hold does not apply to RAPT’s ongoing trial of tivumecirnon (FLX475) in oncology.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
RAPT Therapeutics, Inc. |
|
|
|
|
Date: |
February 20, 2024 |
By: |
/s/ Rodney Young |
|
|
|
Rodney Young |
Document And Entity Information |
Feb. 20, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Feb. 20, 2024 |
Entity Registrant Name | RAPT Therapeutics, Inc. |
Entity Central Index Key | 0001673772 |
Entity Emerging Growth Company | true |
Entity File Number | 001-38997 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 47-3313701 |
Entity Address, Address Line One | 561 Eccles Avenue |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | (650) |
Local Phone Number | 489-9000 |
Entity Information, Former Legal or Registered Name | Not Applicable |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Ex Transition Period | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | RAPT |
Security Exchange Name | NASDAQ |
B2M :.L*+(>P"H<,$E$)VTE
M/"[4;/(^2>MYW'=%P3' W,
M4+ @RE6;=N44+BJP J90K1C"J&Q0P&R&G.V7,S,-HP$R43T !$E(/^>MG/>)
M!$^T#,>@=UEW?2=R$8D$/.%6#5T! 10;"U'=^=_V=3P(C1"%SO95^:1ZI>]A
M!CB2G'QMZ?^QNC%_31X+\.SP5419*I2&88++>\=E(2A)J@>A17'#"_AN.84T
MI6U@:"L,/'/B!V:R%K9 4U\?!H6,$QC9CM3EYA6K]U=[IM03])OHD06=#3@>%N./H
M*HX%Y?E:\S#OPSOZD%DG4 A(:80G4TMS:XVVV\0?JO[1M-R/6P#Y4'3RTX^!
M9?K[.;KE">]WL[1.9.ORG62@*(:.@?9:JEJO]*<7S>,%WK-%&(^X!SZ%Z3#X
MSX,()G 9]H*8.)[AV@;SWNI8J*!%X;AF5V+78'X'0 BJ9LY^]2:
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MPQU[Y]N[U0M5W'S[Y/LA(:'CXLBW;; UQ,=9(.TD*.3C$W[JVJW3^T%%+POLSO5SUH=U5.>D'LB^1+^Z69$
M4$LNM6?PP&8TPD[(0^P$D85)0 T,5X'%0Y?1\,T9N'*IST7"8>R(RS4NFV&8
MV ["T/_>URT*B&.$)L%NX,(:V*&'@\#W<1P0R["IYUG$7,VZW9+A1;6;1[68
MKGT1'1_;MFG[AOF*Z'".5O
IMP-)@@BEZ@ J!:R^8<.(9'E91<(6I63M
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M&>AU4,WH5 XZZ)C!3+2-T-IXM^KL_/1XW)&R'!#5*0TV4J:C/#95]5<[+WH
M@F@BU,9F@KK (/JQ",(:!#*F9@&]3SPS?AWF&N XLB(P/LJ @"'XDR